Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 16/20 | 0.62 |
| ▸ | CNR1 | P21554 | 2/20 | 0.62 |
| ▸ | CNR2 | P34972 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | MGLL | Q99685 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182348 | 1.00 | FAAH (0.62) | FAAHCNR1CNR2CYP2C19KCNH2 | |
| SCHEMBL4179823 | 0.99 | FAAH (0.61) | FAAHCNR1CNR2CYP2C19KCNH2 | |
| SCHEMBL4179827 | 0.99 | FAAH (0.61) | FAAHCNR1CNR2CYP2C19KCNH2 | |
| SCHEMBL4182209 | 0.84 | DRD3 (0.52) | FAAH | |
| SCHEMBL4182203 | 0.84 | DRD3 (0.52) | FAAH | |
| SCHEMBL4180075 | 0.82 | FAAH (0.62) | FAAHCNR1CNR2CYP2C19KCNH2 | |
| SCHEMBL4192823 | 0.82 | FAAH (0.57) | FAAHCNR1CNR2CYP2C19KCNH2 | |
| SCHEMBL4195932 | 0.81 | ALDH1A1 (0.55) | CNR1CNR2 | |
| SCHEMBL4195924 | 0.81 | ALDH1A1 (0.55) | CNR1CNR2 | |
| SCHEMBL4184955 | 0.77 | CNR1 (0.47) | FAAHCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181939-A1 | Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders | VERNALIS RESEARCH LIMITED. (GB) | 2009-07-16 | — | — | US | disclosed |
| US-20070173486-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs | VERNALIS RESEARCH LIMITED (GB) | 2007-07-26 | — | — | US | disclosed |
| EP-1618105-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004096794-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDRS | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181939-A1 | Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders | CNR1, CNR2, GPR119 | FAAH 116/4885CNR1 1/4885CNR2 2/4885 |
| US-20070173486-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs | CNR1, CNR2, GPR119 | FAAH 216/4885CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.